Growth Hormone Therapy Monitoring Form for Pediatric Patients
Schedule clinic visits every 3–6 months (more frequently for young children and those with advanced CKD) to systematically monitor treatment response and detect adverse effects 1.
PATIENT INFORMATION
- Name: _________________ MRN: _________ DOB: _________
- Diagnosis: ☐ GH Deficiency ☐ Idiopathic Short Stature ☐ Turner Syndrome ☐ SGA ☐ CKD ☐ Other: _______
- GH Dose: _____ mg/kg/day Start Date: _________ Current Weight: _____ kg
ANTHROPOMETRIC MEASUREMENTS (Every Visit)
| Date | Height (cm) | Height SDS | Weight (kg) | BMI | BMI SDS | Height Velocity (cm/yr) |
|---|---|---|---|---|---|---|
Target: Height velocity increase >2 cm/year over baseline in first year 1
Mid-Parental Height: _____ cm ± _____ cm
PUBERTAL DEVELOPMENT (Annually for children >10 years)
| Date | Tanner Stage | Notes |
|---|---|---|
LABORATORY MONITORING
Every 3–6 Months:
- IGF-1 Level: _____ ng/mL (Reference: _____) Date: _____
- Maintain at 0 SDS for GHD; +1 to +2 SDS for non-GHD indications 2
- Thyroid Function (TSH, Free T4): TSH _____ Free T4 _____ Date: _____
- Glucose/HbA1c: _____ Date: _____ (Monitor closely in obese patients)
- Calcium: _____ Phosphate: _____ Bicarbonate: _____ Date: _____
CKD Patients Only (Every 3 Months for Stage 3-4):
- PTH Level: _____ pg/mL Date: _____ (Hold GH if PTH >500 pg/mL) 1
- eGFR: _____ mL/min/1.73m² Date: _____ (Stop if unexplained decrease)
BONE AGE ASSESSMENT (Annually)
| Date | Chronological Age | Bone Age (Left Wrist X-ray) | BA/CA Ratio | Interpretation |
|---|---|---|---|---|
Action: Discontinue if accelerated bone maturation evident 1
ADHERENCE ASSESSMENT
- Injection Technique Reviewed: ☐ Yes ☐ No
- Missed Doses (past month): _____
- Injection Site Rotation: ☐ Adequate ☐ Needs Education
- Patient/Family Concerns: _________________________________
ADVERSE EFFECTS SCREENING (Every Visit)
Check if present and document:
- ☐ Headaches/Visual Changes (Intracranial hypertension - STOP GH immediately) 1
- ☐ Hip/Knee Pain (Obtain X-ray to rule out slipped capital femoral epiphysis - STOP if confirmed) 1
- ☐ Symptoms of Hyperglycemia (Check glucose/HbA1c)
- ☐ Injection Site Reactions/Lipoatrophy
- ☐ Edema
TREATMENT RESPONSE EVALUATION
First Year Assessment:
Height velocity increase from baseline: _____ cm/year
- If <2 cm/year improvement: 1
- Verify adherence (check IGF-1 level)
- Confirm weight-adjusted dosing
- Reassess nutritional/metabolic factors
- Consider discontinuation if no response after 6 months
Ongoing Assessment:
- Height SDS Change: _____ (Goal: normalize adult height)
- Approaching Genetic Target Height: ☐ Yes ☐ No
- Growth Velocity <2 cm/year in late puberty: ☐ Yes ☐ No
CRITERIA FOR DISCONTINUATION 1
STOP GH immediately if:
- ☐ Epiphyseal closure on X-ray
- ☐ Renal transplantation performed
- ☐ PTH >500 pg/mL (CKD patients - may restart when controlled)
- ☐ Intracranial hypertension
- ☐ Slipped capital femoral epiphysis
- ☐ Unexplained eGFR decrease
- ☐ Accelerated bone maturation
- ☐ No response despite optimal control for 6+ months
Consider discontinuation if:
- ☐ Genetic target height percentile reached
- ☐ Growth velocity <2 cm/year with closed/closing growth plates
NEXT VISIT PLAN
Date: _________ Interval: ☐ 3 months ☐ 6 months
Labs Needed: ☐ IGF-1 ☐ Thyroid ☐ Glucose ☐ Metabolic Panel ☐ PTH (CKD)
Imaging: ☐ Bone Age ☐ Other: _______
Provider Signature: _________________ Date: _________